From chimpanzee coryza to palivizumab: changing times for respiratory syncytial virus.
Ogra
P L
PL
Department of Pediatrics, State University of New York at Buffalo, School of Medicine and Biomedical Sciences and Children's Hospital of Buffalo, USA. pogra@upa.chob.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D000069455:Palivizumab; D002679:Pan troglodytes; D011379:Prognosis; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects* / Q000502:physiology; D012307:Risk Factors; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab